PURPOSE: Provided are novel 5-HT1F agonists which inhibit peptide extravasation due to stimulation of the trigeminal ganglia, and are therefore useful for the treatment and prevention of migraine and associated disorders. CONSTITUTION: Provided are novel 8-substituted1,2,3,4-tetrahydro-2-dibenzofuranamines and 9-substituted-2 aminocyclohepta£b|benzofurans of Formula I: wherein: R1 and R2 are independently hydrogen, C1-C4 alkyl, benzyl, or a-methyl-4-nitrobenzyl; X is nitro, halo, -OH, -NH2, -CN, -NHC(O)R3, -C(O)R6, -NHSo2R7, or -SO2NHR10; R3 is C1-C6 alkyl, C2-C6 alkenyl, C3-Cg cycloalkyl, phenyl, substituted phenyl, naphthyl, phenyl(C1-C4 alkylene), thienylmethyl, or a heterocycle; R6 is hydroxy, amino, C1-C6 alkoxy, benzyloxy, phenoxy, or -NHR8; R7 is C1-C6 alkyl, phenyl or phenyl mono substituted with halo or C1-C4 alkyl; R8 is C1-C6 alkyl, C2-C6 alkenyl, C3-Cg cycloalkyl, phenyl, substituted phenyl, naphthyl, or a heterocycle; and R10 is C1-C6 alkyl, phenyl or phenyl mono substituted with halo or C1-C4 alkyl; m is 1 or 2; and pharmaceutically acceptable salts thereof.
SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[B]BENZOFURANS